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Hepatitis A virus is an hepatotrophic human picornavirus which demonstrates little antigenic variability. To
topologically map immunogenic sites on hepatitis A virus which elicit neutralizing antibodies, eight neutralizing
monoclonal antibodies were evaluated in competition immunoassays employing radiolabeled monoclonal
antibodies and HM-175 virus. Whereas two antibodies (K3-4C8 and K3-2F2) bound to intimately overlapping
epitopes, the epitope bound by a third antibody (B5-B3) was distinctly different as evidenced by a lack of
competition between antibodies for binding to the virus. The other five antibodies variably blocked the binding
of both K3-4C8-K3-2F2 and B5-B3, suggesting that these epitopes are closely spaced and perhaps part of a
single neutralization immunogenic site. Several combinations of monoclonal antibodies blocked the binding of
polyclonal human convalescent antibody by greater than 96%, indicating that the neutralization epitopes
bound by these antibodies are immunodominant in humans. Spontaneously arising HM-175 mutants were
selected for resistance to monoclonal antibody-mediated neutralization. Fourteen clonally isolated mutants
demonstrated substantial resistance to multiple monoclonal antibodies, including K3-4C8-K3-2F2 and B5-B3.
In addition, 13 mutants demonstrated a 10-fold or greater reduction in neutralization mediated by polyclonal
human antibody. Neutralization resistance was associated with reduced antibody binding. These results suggest
that hepatitis A virus may differ from poliovirus in possessing a single, dominant neutralization immunogenic
site and therefore may be a better candidate for synthetic peptide or antiidiotype vaccine development.
Hepatitis A virus (HAV) accounts for 38% of cases of viral
hepatitis reported annually in the United States (6). On the
basis of morphologic and biophysical characteristics, HAV
has been classified among the Picornaviridae (5). Like
poliovirus, the virion is a naked icosahedron. The capsid
contains at least three major structural proteins (VP1, VP2,
VP3), of which VP1 appears to be the dominant surface
protein (2). Only a single antigenic specificity has been
associated with HAV, and significant antigenic variation has
not been recognized among different HAV strains (14).
Denaturation of the virus leads to a loss of antigenicity,
suggesting that the relevant antigenic sites are strictly
conformationally dependent (10; J. T. Stapleton, and S. M.
Lemon, unpublished data). By covalently cross-linking
monoclonal antibodies to intact HAV, one major antigenic
site has been located on VP1 (10).
Analysis of mutants that are resistant to neutralizing
monoclonal antibodies has proven useful for identifying
immunogenic sites involved in the neutralization of other
picornaviruses (3, 20, 24). Genomic nucleotide substitutions
associated with neutralization resistance, when analyzed in
the context of the three-dimensional structure of poliovirus
type 1 (PV1) or human rhinovirus type 14 (HRV14), have
identified multiple discrete sites on the virion surface which
appear to function both as immunogens and as attachment
sites for neutralizing monoclonal antibodies (8, 22). Four
such neutralization immunogenic sites have been identified
on both PV1 and HRV14; they involve all three surface
polypeptides (8, 23). In general, mutation occurring within
one neutralization immunogenic site has conferred resis-
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tance to all monoclonal antibodies binding at that site, but
not to those binding at alternate sites.
To identify the neutralization immunogenic sites of HAV,
we selected neutalization escape mutants that resist neutral-
ization mediated by a panel of murine monoclonal antibod-
ies. Unlike PV1 and HRV14, characterization of these
antibodies and related neutralization escape mutants sug-
gests the existence of only a single neutralization immuno-
genic site on the HAV virion. Furthermore, this immuno-
genic site is dominant in human antibody responses to
natural infection.
MATERIALS AND METHODS
Cells. Continuous African green monkey kidney (BS-C-1)
cells (passages 58 to 87) were cultivated as described previ-
ously (25).
Virus. The cell culture-adapted HM-175 strain of HAV
had previously been passaged 10 times in African green
monkey kidney cells and 5 times in Bs-C-1 cells (1). A stock
virus seed was prepared from tissue culture supernatant
fluids and extracted twice with equal volumes of chloroform
(25). The infectivity titer of this HM-175 seed was approxi-
mately 106 radioimmunofocus-forming units per ml (15). For
immunoassays, virus was concentrated from cell culture
supernatant fluids and purified by isopycnic banding in
cesium chloride (18).
Antibodies. Murine monoclonal antibodies raised against
HAV were kindly provided by three other laboratories.
Ascitic fluids containing monoclonal antibodies K3-4C8,
K2-4F2, and K3-2F2 were obtained from A. G. Coulepis and
I. D. Gust, Melbourne, Australia (19); B5-B3 was the gift of
R. S. Tedder, London, United Kingdom; and 6A5, 1B9,
2D2, and 3E1 were provided as concentrated hybridoma
tissue culture supernatant fluids by J. V. Hughes, E. A.
Emini, and R. Gerety, West Point, Pa. (10). Characteristics
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TABLE 1. Murine monoclonal anti-HAV antibodies
Antibodya Isotype Immunizing titeri Sourcec
K3-4C8 IgG2a HM-790 >5.0 A
K2-4F2 IgG2a HM-790 >5.0 A
K3-2F2 IgG2a HM-790 >5.0 A
B5-B3 IgG2a KMW-1 5.1 B
6A5 IgG2a CR-326 6.0 C
1B9 IgGl CR-326 3.5 C
2D2 IgG2a CR-326 5.4 C
3E1 IgG2a CR-326 4.0 C
a 6A5, 1B9, 2D2, and 3E1 were supplied as concentrated hybridoma tissue
culture fluids, whereas other antibodies were ascitic fluids.
bLog1o of the antibody dilution effecting 50% neutralization of HM175 virus
in the radioimmunofocus inhibition assay (15).
c A, A. G. Coulepis and I. D. Gust, Fairfield Hospital, Melbourne, Australia
(19); B, R. S. Tedder, Middlesex Hospital, London, United Kingdom, C, J. V.
Hughes, E. A. Emini, and R. Gerety, Merck Sharp and Dohme Research
Laboratories, West Point, Pa. (10).
of these monoclonal antibodies are shown in Table 1. Poly-
clonal human sera were obtained from patients convalescing
from HAV infection acquired in Africa (JC-pcAb) or Alaska
(Sm-pcAb). Commercial immune serum globulin (lot no.
NFOO35-2) was purchased from Cutter Laboratories,
Berkley, Calif. Immunoglobulin G (IgG) was purified from
human sera by ammonium sulfate precipitation followed by
passage through DEAE-Sephacel (Pharmacia Fine Chemi-
cals, Piscataway, N.J.) (16). Murine ascitic fluid IgG frac-
tions were obtained by ammonium sulfate precipitation.
Radioiodination of individual IgG fractions was carried out
by a modification of the chloramine T method (16). Mono-
clonal antibodies were quantitated by a solid-phase, isotype-
specific, enzyme-linked immunosorbent assay.
Solid-phase monoclonal antibody competition assay. The
ability of individual monoclonal antibodies to competitively
block the binding of other monoclonal and polyclonal anti-
bodies was determined in competitive radioimmunoassays.
Briefly, 100 R1 of an anti-HAV positive serum (JC-pcAb),
diluted 1:1,000 in 50 mM sodium carbonate buffer pH 9.6,
was applied to wells of a polyvinyl chloride microtiter plate
(Dynatech Laboratories, Inc., Alexandria, Va.) for 4 h at
37°C. After two washes with phosphate-buffered saline
(PBS) containing 0.05% Tween 80, 50 ,ul of a suspension
containing gradient-purified HM-175 HAV was applied and
incubated overnight at 4°C. After two further washes with
PBS-Tween 80, 25-,ul samples of fivefold dilutions of each
antibody (1:5 to 1:3125) in PBS were applied to two replicate
wells and allowed to incubate for 15 min before the addition
of 25 RI1 of a solution containing 200,000 cpm of 125I-labeled
monoclonal or polyclonal IgG diluted in PBS containing 10%
fetal bovine serum. After 4 h of incubation at 4°C, the wells
were washed extensively and cut out, and residual bound
1251 was determined with an LKB Rackgamma gamma
counter (LKB Instruments, Turku, Finland).
In vitro neutralization assay. Quantitation of infectious
HAV was carried out by a radioimmunofocus assay (15).
This technique is similar to standard viral plaque assays,
except that foci of viral replication (radioimmunofoci) are
detected by autoradiography after the removal of the agarose
overlay, acetone fixation of the cell sheet, and staining with
125I-labeled polyclonal antibody (Sm-pcAb). Neutralizing
anti-HAV antibody was detected by inhibition of radioim-
munofocus formation (13) and was considered present if
incubation of a sample with virus resulted in a 50% or greater
reduction in the number of observed radioimmunofoci.
Clonal isolation of HAV. Clonal mutants of HAV were
isolated from radioimmunofocus assay cultures as described
previously (17), but with minor modifications. After the
period of viral growth, the orientation of the agarose overlay
within individual petri dishes was marked. The intact over-
lay was peeled from the cell sheet and placed inverted at 4°C
until the completion of the radioimmunofocus assay and the
development of the autoradiograms. The inverted overlay
was then carefully realigned over the autoradiogram to its
original position, and agarose plugs overlying individual
radioimmunofoci were removed with a Pasteur pipette. The
agarose plug was suspended in 0.75 ml of Hanks balanced
salt solution containing 5% fetal bovine serum, freeze-
thawed once, and extracted with an equal volume of chlo-
roform. The resulting HAV suspension was subjected to two
additional such cycles of plaque purification, and virus was
amplified in 24-well tissue culture clusters (Costar, Cam-
bridge, Mass.) containing BS-C-1 cell monolayers. Agarose
harvested from multiple regions not overlying radioim-
munofoci did not yield virus.
HAV neutralization escape mutants. Chloroform-ex-
tracted, cell culture-adapted HM-175 HAV was mixed with
an equal volume of monoclonal or polyclonal antibody
diluted to 10-4.5 in Hanks balanced salt solution containing
5% fetal bovine serum and incubated for 1 h at 37°C. Longer
incubation periods did not lead to enhancement of viral
neutralization. Nonneutralized virus was amplified in BS-C-
1 cell cultures maintained in medium containing the related
antibody at the same concentration employed in the neutral-
ization reaction. Medium containing antibody was replaced
twice weekly, and supernatant culture fluids were assayed
for HAV by cDNA-RNA slot-blot hybridization (11). Super-
natant fluids had detectable HAV 20 days postinoculation.
This supernatant fluid was chloroform extracted and sub-
jected to a second neutralization reaction followed by am-
plification in the presence of higher concentrations of anti-
body (10-3-5). HAV was detectable by hybridization in
supernatant fluids 17 days after inoculation of cultures with
this virus. Cells were refed with antibody-free medium, and
virus subsequently released into supernatant fluids was
chloroform extracted and assayed for susceptibility to neu-
tralization with a 10-2 dilution of the related antibody. After
this neutralization reaction, neutralization-resistant mutants
were clonally isolated from radioimmunofocus assay cul-
tures as described above. Altogether, 29 mutants underwent
two additional neutralization and clonal selection cycles and
were amplified in BS-C-1 cells for further characterization.
HAV released into the supernatant fluids of these cultures
was chloroform extracted before further study.
cDNA-RNA hybridization. An HAV cDNA probe was
prepared as described previously (11) from E. coli cultures
containing the recombinant plasmid pHAVLB1307, which
has an insert of cDNA complementary to HM-175 virion
RNA (26). E. coli cultures were the gift of J. Ticehurst of the
National Institute of Allergy and Infectious Diseases, Be-
thesda, Md. (26). Direct blotting (11) of HAV suspensions
onto nitrocellulose paper was accomplished with the
Minifold-TI slot-blot apparatus (Schleicher & Schuell Co.,
Keene, N.H.). Virus samples were diluted into 0.55 ml of
blotting buffer (4.61 M formaldehyde in 7.5x SSC, lx SSC
consists of 0.15 M NaCl-0.015 M sodium citrate) and applied
directly to the nitrocellulose paper followed by a single wash
with lOx SSC. The nitrocellulose was dried at 23°C for 30
min and then baked at 80°C for 2 to 6 h in a vacuum oven.
Prehybridization was carried out for at least 3 h at 42°C with
denatured calf thymus DNA (0.1 mg/ml) in prehybridization
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buffer (50% formamide, 2.5 x Denhardt solution, 5 x SSC,
0.1% sodium dodecyl sulfate). 32P-labeled HAV cDNA in-
sert probes were boiled for 3 min and added to hybridization
buffer (identical to prehybridization buffer except for lx
Denhardt solution) to a final concentration of 1 x 106 to 1.5
x 106 cpm/ml. Hybridization was carried out at 42°C for 22
to 48 h in sealed plastic bags. Nitrocellulose papers were
washed twice in 2 x SSC-0. 1% sodium dodecyl sulfate at
room temperature, followed by two washes in 0.1 x
SSC-0.1% sodium dodecyl sulfate at 52°C. Annealed cDNA
was detected autoradiographically after exposure to X-AR5
film (Eastman Kodak Co., Rochester, N.Y.) for 16 h at
-70°C with X-Omat intensifying screens (Kodak).
Immunoaffinity hybridization. The ability of monoclonal
and polyclonal antibodies to bind to selected neutralization-
resistant HAV mutants was assessed in a modified im-
munoaffinity hybridization assay (11). Wells of a polyvinyl
microtiter plate were coated with 100 ,ul of individual anti-
bodies diluted 1:500 in 50 mM sodium carbonate buffer (pH
9.6) for 4 h at 37°C. A 100-,ul sample of 1% bovine serum
albumin was added to each well during the last hour of this
incubation to prevent nonspecific binding of virus in subse-
quent steps. After aspiration of the wells and five washes
with PBS-Tween 80, 100 R1 samples of tissue culture super-
natant fluids were added to individual wells and incubated
for 16 h at 4°C. The contents of each well (representing virus
not bound to the antibody) were aspirated and blotted
directly onto nitrocellulose paper. The microtiter wells were
then washed five times with PBS-Tween 80, and 100 [L1 of
0.1 N HCI was added for 30 min at room temperature to elute
virus bound to the wells. The contents of each well (now
representing virus which had been bound to antibody) were
subsequently blotted to nitrocellulose as above. Parental
virus (normal HM-175 HAV) was included as a positive
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RECIPROCAL BLOCKING ANTIBODY DILUTION
FIG. 1. Competitive inhibition of K3-4C8 and K2-4F2 monoclo-
nal antibody binding to HM-175 virus in solid-phase radioimmunoas-
says. Various monoclonal antibodies (--- - and * *) and polyclonal
sera ( ) were tested for their ability to inhibit the binding of
251I-labeled K3-4C8 (A) or K2-4F2 (B) to HM-175 virus as described
in the text. Symbols: (0) preimmune chimpanzee sera, (0) JC-
pcAb, (0) B5-B3 (O) K2-4F2 (A) K3-4C8, (A) K3-2F2. Each data
point represents the mean of two replicate assay determinations.
Results were reproducible.
TABLE 2. Competitive inhibition of monoclonal antibody binding
to HM-175 virus in solid-phase radioimmunoassays
Competing Inhibition of radiolabeled antibodya
antibody K3-4C8 K3-2F2 K2-4F2 B5-B3
K3-4C8 + + + + + + + + ++++ 0
K3-2F2 + + + + ++++ ++++ 0
6A5 + + + + ++++ + +++ ++
K2-4F2 + + + + ++++ ++++ + +
1B9 + + + + ++++ + + + + + + +
2D2 + + + + ++++ + + + + + + +
3E1 + + + + ++++ + + + + + + +
B5-B3 0 0 0 + + + +
a Results shown are with dilutions of competing antibodies ranging from 16
to 50 j±g/ml. 0, <20% reduction in counts per minute with the addition of
competing antibody compared with preimmune sera; +, 20 to <40% reduc-
tion; + +, 40 to <60%o reduction; + + +, 60 to <80% reduction; + + + +, 80
to 100% reduction. Results shown represent the mean counts per minute
obtained in replicate microtiter wells in immunoassays and were confirmed in
repeat experiments.
directed against HAV was employed as a negative binding
control. Blots were subjected to cDNA-RNA hybridization
as described above.
RESULTS
Topologic mapping of HAV neutralization epitopes. Each of
the eight monoclonal antibody preparations possessed high-
titered neutralizing activity against HM-175 strain HAV
when assayed in a radioimmunofocus inhibition assay (13),
although all were derived from mice immunized with other
strains of virus (Table 1).
To characterize epitopes recognized by these monoclonal
antibodies, competitive radioimmunoassays were estab-
lished employing individual radiolabeled monoclonal anti-
bodies. Figure 1 depicts representative preliminary experi-
ments in which multiple dilutions of several different
antibodies were tested for their ability to compete for
binding with radiolabeled K2-4F2 or K3-4C8. These and
similar experiments indicated that K2-4F2, K3-4C8, and
K3-2F2 were directed against closely overlapping neutraliza-
tion epitopes, since these three monoclonal antibodies com-
peted with each other for binding to the virus to a very high
degree. In contrast, B5-B3 did not block the binding of
radiolabeled K2-4F2 to HM-175 (Fig. 1A) and thus appeared
to recognize a distinct epitope. High concentrations of
B5-B3 resulted in a moderate reduction of K3-4C8 binding,
however (Fig. 1B), whereas some concentrations of B5-B3
caused a reproducible enhancement of K2-4F2 binding (Fig.
1A). These results suggested that these epitopes are closely
spaced. Additional data obtained with the complete panel of
antibodies are summarized in Table 2. The data in Table 2
are derived from experiments in which the concentration of
the unlabeled antibody ranged from 16 to 50 jig/ml and was
in considerable excess over the concentration of the labeled
monoclonal antibody (<0.5 ,ug/ml). Monoclonal antibodies
6A5, K2-4F2, 1B9, 2D2, and 3E1 all showed varied abilities
to compete for binding with radiolabeled K3-4C8, K3-2F2,
K2-4F2, and B5-B3, further suggesting that the epitopes
recognized by each of these monoclonal antibodies are
closely spaced on the capsid surface and part of a single
functional antigenic domain.
Immunodominance of neutralization epitopes. Most of the
monoclonal antibodies were found to compete effectively,
but not completely, with radiolabeled human polyclonal
antibody for binding to HM-175 HAV in solid-phase radioim-
VOL. 61, 1987
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TABLE 3. Competitive inhibition of polyclonal human
convalescent antibody binding to HM-175 virus by monoclonal
antibodies, alone or in combination




None (PBS) 4,304-5,900 (0%) 4,542-3,588 (0)
1B9 3,090-3,022 (40) ND
K3-4C8 2,674-2,739 (47) 2,073-1,950 (51)
B5-B3 2,118-1,962 (60) 1,150-1,118 (72)
6A5 2,292-1,641 (62) ND
3E1 1,834-1,735 (65) ND
K3-4C8-K2-4F2 1,629-1,672 (68) 924-804 (79)
2D2 1,577-1,377 (71) ND
K2-4F2 1,242-1,210 (76) 1,225-1,365 (69)
6A5-3E1 1,191-1,216 (76) ND
K3-4C8-B5-B3 189-190 (96) 92-136 (97)
6A5-B5-B3 142-112 (99) ND
K2-4F2-B5-B3 76-52 (99) 55-49 (99)
a Competing antibodies were present at dilutions yielding maximum inhibi-
tion in single antibody competition immunoassays.
b Results are given as the range of counts per minute in replicate microtiter
plate wells, with the percent reduction from PBS control wells given within
parentheses. ND, Not done.
munoassays (Table 3). B5-B3 and K2-4F2 were roughly
equivalent in their ability to compete with radiolabeled
polyclonal Sm-pcAb (Fig. 2) or JC-pcAb (antibodies ob-
tained during convalescence from two naturally infected
humans), but were additive in their inhibitory effects. A 1:1
mixture of B5-B3 and K2-4F2 was equivalent to JC-pcAb in
blocking the binding of either Sm-pcAb or JC-pcAb to the
virus, indicating that a mixture of these two antibodies is
able to block the binding of greater than 99% of the antibod-
ies elicited during natural human infections (Table 3). Other
combinations of monoclonal antibodies demonstrated vari-
able degrees of additive effects in inhibiting the binding of
radiolabeled polyclonal antibodies to the virus (Table 3).
Together, the data presented in Tables 2 and 3 suggest that
the neutralization epitopes recognized by these eight mono-
clonal antibodies form a closely spaced, immunodominant
cluster on the capsid surface, although alternative interpre-
tations (i.e., inhibition of antibody binding due to induced
changes in capsid conformation) are possible and are con-
sidered below (see Discussion).
Neutralization escape mutants of HAV. A multistep selec-
tion process was employed to select virus resistant to
neutralization with K2-4F2, K3-4C8, B5-B3, and polyclonal
human serum (JC-pcAb). HM-175 HAV was incubated with
a dilution of monoclonal or polyclonal antibody that was
approximately 10-fold that required to effect 50% neutraliza-
tion (endpoint neutralization titer), and surviving virus was
propagated in the presence of the same concentration of
antibody. Approximately 99% of first-passage HAV survi-
vors selected in this fashion were resistant to a concentration
of each related antibody that was 100-fold the endpoint
neutralization titer (higher concentrations of antibody were
not tested) (data not shown). This supernatant virus was
chloroform extracted, and the selection cycle was repeated
under pressure of 10-fold higher concentrations of antibody.
Second-passage virus released into supernatant culture
fluids in the absence of antibody was resistant to a concen-
tration of antibody that was 300-fold the endpoint neutral-
ization titer of that antibody when tested against normal
HM-175 virus (data not shown). This included virus selected
in the presence of polyclonal antibody. Second-passage
mutant virus was subjected to a high-stringency neutraliza-
tion reaction (10-2 dilution of antibody) and plaque purified
through three cycles as described in Materials and Methods
(the antibody concentration was 3,000-fold the endpoint
neutralization titer). Twenty-nine neutralization escape mu-
tants were clonally isolated and amplified in BS-C-1 cells in
the presence of low antibody concentrations. These mutants
resisted neutralization by the homologous antibody (Fig. 3).
Because of the nature of the selection process, it is possible
that some of these neutralization escape mutants represent
sibling clones.
The genetic stability of three different HM-175 mutants
was assessed during a single passage in 890-cm2 roller bottle
cultures of BS-C-1 cells, both in the presence and absence of
the relevant antibody (10-' dilution). Virus released into the
cell culture supernatant fluid 32 days after inoculation was
tested for neutralization resistance. In each case, less than a
threefold reduction in infectious titer followed incubation of
the virus with a 10-2 concentration of antibody, confirming
the genetic stability of the mutations. There was no differ-
ence between the neutralization resistance of virus propa-
gated in the presence or absence of the related antibodies.
Antibody binding to neutralization-resistant HAV mutants.
Resistance to neutralizing monoclonal antibodies could be
conferred by mutations altering the ability of antibodies to
bind to the viral capsid or by mutations that block the capsid
conformational changes that are thought to accompany
neutralization of picornaviruses such as poliovirus after the
bivalent binding of some monoclonal antibodies (4). To
assess these alternative possibilities, neutralization escape
mutants were examined for their ability to bind their cognate
antibodies. First, mutant 18 (selected against K2-4F2) was
amplified in an 890-cm2 roller bottle culture of BS-C-1 cells














FIG. 2. Two monoclonal antibodies (--- - and ...) and poly-
clonal sera ( ) were tested for their ability to inhibit the binding
of radiolabeled polyclonal antibody Sm-pcAb to HM-175 virus.
Symbols: (0) preimmune chimpanzee serum, (0) B5-B3, (O)
K2-4F2, (G) a 1:1 mixture of B5-B3 and K2-4F2, (0) JC-pcAb. See
legend to Fig. 1.
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FIG. 3. Clonally isolated, neutralization-resista
tants. Viruses selected for resistance to monoc
K3-4C8, K2-4F2, and B5-B3 and the human polyc
JC-pcAb were harvested in the absence of antibe
extracted, and quantitated by radioimmunofocus a
and after (B) neutralization with a 1:3,000 dilt
antibody; thus, foci in (B) represent nonneutralize
diograms in (C) represent cells inoculated with p
subjected to identical neutralization reactions. An a
cells inoculated with parental virus not reacted N
shown at the top of (C).
banding in cesium chloride. The density grac
mutant 18 was similar to that of the parental
with the major peak of virus at 1.32 to 1.33 g
shown). Specifically, there was no increase
particle fraction banding at 1.40 to 1.44 g/cm3,
the capsid mutation associated with neutraliza
had not altered the normal impermeability o0
cesium (18). The ability of radiolabeled
K2-4F2 antibodies to bind to mutant 18 and pa
viruses was assessed in solid-phase radioii
Microtiter wells were coated with JC-pcAb
above and incubated overnight at 4°C with gra
containing purified viruses. The wells were
sively, radiolabeled Sm-pcAb or K2-4F2 was
assay was completed as described above. 1
radiolabeled K2-4F2 was markedly decreased,
binding of polyclonal Sm-pcAb, when mutan
pared with the HM-175 control (Table 4). The
that the neutralization resistance of mutant
ated with a substantially reduced affinity of ti
w monoclonal antibody (K2-4F2) against which it had been
selected.
To further assess this hypothesis, the ability of individual
w monoclonal and polyclonal antibodies to bind to selected
mutants was determined by immunoaffinity hybridization.
*b*,*-; This approach was taken in lieu of radioimmunoprecipitation
because of the difficulties inherent in radiolabeling HAV
C endogenously (due to the lack of inhibition of host cell
protein synthesis). Antibody was coated onto the surface of
microtiter plate wells. Virus suspensions were incubated in
the antibody-coated wells overnight, and unbound virus and
virus bound to antibody were assessed by cDNA-RNA
hybridization as described in Materials and Methods. Figure
4 depicts the hybridization signals achieved with HAV
mutants binding to their cognate antibodies. This was com-
pared with the hybridization signal achieved with virus not
bound to antibody after an overnight incubation. Approxi-
mately 50% of the parental HM-175 virus included as a
control was bound to antibody when slot-blot hybridization
results were measured quantitatively by densitometry (data
not shown). In contrast, neutralization-resistant mutants
were bound to their related antibodies to a much lesser
degree, in agreement with the hypothesis that neutralization
resistance was conferred by altered affinity of monoclonal
antibodies for the immunodominant site on the virus capsid.
Selected mutants were also evaluated for binding to three
unrelated monoclonal antibodies and the polyclonal anti-
body JC-pcAb (data not shown). Although largely qualita-
tive, these experiments suggested that the binding of the
mutants to most monoclonal antibodies was decreased when
compared with parental virus. Additionally, the amount of
each mutant binding to polyclonal antibody appeared dimin-
ished (albeit to a lesser degree than with monoclonal anti-
body) when mutants were compared with parental virus.
mnt HM-175 mu- This finding is consistent with the presence of an im-
lonal antibodies munodominant antigenic site.
clonal antiserum Cross-resistance between neutralization-resistant mutants.
dy, chloroform- Different neutralization immunogenic sites on PV1 and
ution of related HRV14 have been defined by grouping neutralization escape
d virus. Autora- mutants with resistance among, but not between, various
)arental HM-175 groups of monoclonal antibodies (3, 20, 21, 24). Thus it was
tutoradiogram of of interest to determine whether HAV escape mutants
with antibody is resistant to any one antibody would be broadly resistant to
other monoclonal antibodies in the panel. Mutants were
characterized for resistance to selected monoclonal and
polyclonal antibodies (including immune serum globulin
dient profile of which contains antibody from a large number of human
HM-175 virus, donors) by assessing the reduction in infectious titer after
'/cm3 (data not neutralization with a 10-2 dilution of antibody. Each of the
in the heavy antibodies employed in these experiments possessed a 50%
indicating that neutralization titer in excess of l0-5. Approximately 105
tion resistance RFU of virus was mixed with an equal volume of antibody
f the capsid to and incubated for 1 h at 37°C. The mixture was diluted
Sm-pcAb and serially in 10-fold increments and assayed by radioim-
rental HM-175
mmunoassays.




, relative to the
it 18 was com-
se data suggest
18 was associ-
te virus for the
Mean cpm bound
I-anti-HAV
HM-175 Mutant 18( +)a Mutant 18(-)a
Sm-pcAb 5,856 6,331 3,991
K2-4F2 5,664 708 549
aMutant 18 ways purified from infected 890-cm2 roller bottle cultures in the
presence (+) or absence (-) of K24F2 antibody. Results shown represent the
mean of two replicate determinations.
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FIG. 4. Immunoaffinity hybridization results obtained with selected neutralization-resistant mutants and related monoclonal antibodies
(K3-4C8, K2-4F2, B5-B3) and polyclonal antibodies (JC-pcAb). Virus suspensions were incubated in antibody-coated microtiter plate wells
overnight, and unbound virus and virus bound to antibody were assessed by cDNA-RNA hybridization as described in the text. P, Parental
HM-175 HAV. Numbers represent the laboratory designations for the mutants tested.
munofocus assay. Although the neutralization resistance of
mutants was generally greatest with the cognate monoclonal
antibody, extensive cross-resistance among other monoclo-
nal antibodies was exhibited by many mutants (Table 5).
Additionally, resistance of selected mutants extended to
6A5, 1B9, 2D2, and 3E1 as well (data not shown). The
mutants that demonstrated the highest degree of homologous
resistance and that were the most broadly cross-resistant to
other monoclonal and polyclonal antibodies were those
selected for resistance to K2-4F2. Of the three monoclonal
antibodies used in selection of neutralization escape mu-
tants, this antibody had the broadest ability to compete with
other monoclonal antibodies in competition immunoassays
(Table 2) and was able to effectively block the binding of
both K3-4C8 and B5-B3 antibodies to virus. Cross-resistance
of escape mutants extended to both B5-B3 and K3-2F2
antibodies, even though there were no apparent interactions
between these antibodies in competitive binding assays.
These observations strongly support the concept that the
epitopes bound by K3-4C8, K2-4F2, and B5-B3 are part of a
single functional neutralization immunogenic site.
Many mutants selected for resistance to monoclonal anti-
bodies demonstrated a greater than 10-fold reduction in
neutralization by polyclonal JC-pcAb and immune serum
globulin when compared with the parental virus (Table 5).
This finding is consistent with the immunodominant nature
of the major immunogenic neutralization site. Mutant 57
demonstrated greater than a 100-fold decrease in polyclonal
antibody-mediated neutralization, but this virus could have
acquired multiple mutations during the multistep selection
process against polyclonal antibody (Jc-pcAb).
DISCUSSION
The eight anti-HAV monoclonal antibodies recognize sev-
eral distinct epitopes as shown by the results of competitive
radioimmunoassays. Two distinct epitopes without apparent
functional overlap were identified by B5-B3 and K3-4C8.
However, close proximity of these epitopes was suggested
by competition between K2-4F2 (which overlaps extensively
with K3-4C8) and B5-B3 and confirmed by analysis of
monoclonal antibodies 6A5, 1B9, 2D2, and 3E1. These latter
antibodies recognize epitopes that overlap both B5-B3,
K3-2F2, and K3-4C8 to variable degrees (Table 2), suggest-
ing that all of these epitopes are closely clustered on the
capsid surface. Several different combinations of monoclo-
nal antibodies that showed minimal competition with each
other for binding to the virus (e.g., B5-B3 and K2-4F2) were
capable of almost completely blocking the binding of radio-
TABLE 5. Resistance of HM-175 virus mutants to neutralization with monoclonal and polyclonal antibodiesa
Selection Monoclonal antibody Polyclonal antibody
Mutant against K3-4C8 K2-4F2 K3-2F2 B5-B3 JC ISG
1 K3-4C8 0.3 0.6 0.4 0.1 0.5 1.0
8 K3-4C8 1.2 1.2 1.0 0.4 0.4 1.5
18 K2-4F2 0.5 -0.2 0.0 0.1 1.2 1.4
19 K2-4F2 0.8 0.1 0.2 0.3 1.6 2.4
20 K2-4F2 0.4 -0.1 0.0 0.2 0.8 1.0
23 K2-4F2 1.1 0.3 0.7 0.6 1.5 1.6
27 K2-4F2 0.7 0.1 0.2 0.1 1.0 1.2
28 K2-4F2 0.9 0.2 0.7 0.5 1.1 1.6
30 K2-4F2 0.2 0.4 0.4 0.6 1.7 1.5
32 B5-B3 0.7 0.8 0.7 0.3 1.0 1.1
33 B5-B3 0.7 0.9 0.6 0.2 1.0 1.5
34 B5-B3 1.1 1.1 1.1 0.4 1.3 1.3
36 B5-B3 1.3 1.2 0.5 1.4 2.1
57 JC 0.4 0.4 0.4 0.2 0.4 0.8
HM 175b 2.-42.8 2.5-2.6 1.6-1.8 1.3-2.4 2.5-3.2 2.9-3.9
aThe data for all mutants but HM-175 represent the greatest loglo reduction in infectious titer of virus after I h of incubation with a 10-2 dilution of antibody
in duplicate experiments.
bThe data for HM-175 represent the range of loglo reductions in titer of parental virus in four separate experiments.
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labeled human polyclonal antibodies (Table 3). Thus, the
monoclonal antibodies appear to be directed against compo-
nents of a single functional domain that is immunodominant
in naturally infected humans as well as in experimentally
immunized mice.
Although the results of these competition experiments are
consistent with direct competition between antibodies at
their respective epitopes, other possibilities need to be
considered. Reduced binding of radiolabeled antibody in
competition immunoassays could occur as a result of a
capsid conformational change induced by binding of the
nonlabeled antibody. However, this interpretation appears
unlikely for the following reasons. The variable inhibition of
B5-B3 binding by other monoclonal antibodies (Table 2)
could be explained only by multiple different capsid
conformational states, whereas available evidence derived
from studies with poliovirus supports the existence of only
two alternate capsid conformations (4). Similarly, the addi-
tive effect of several combinations of antibodies in blocking
the binding of polyclonal antibody (Table 3) is difficult to
explain on the basis of conformational changes, because this
would also require the existence of multiple conformational
states. These considerations, and the fact that combinations
of noncompeting monoclonal antibodies were most likely to
show significant additive effects in blocking the binding of
polyclonal antibody, suggests competition at the antibody
binding site. An additional consideration is that the binding
of antibody to any antigenic site on a picornavirus could in
theory interfere nonspecifically with the binding of other
antibodies due simply to crowding on the virion surface.
This, however, was not observed with K3-4C8-K3-2F2 and
B5-B3 which did not compete with each other under the
conditions employed (Table 2).
The existence of a single immunodominant neutralization
site on the HAV capsid was further suggested by analysis of
spontaneously occurring HAV mutants that were resistant to
monoclonal antibody-mediated neutralization. Mutants were
selected by passage of HM-175 virus in the presence of
either individual murine monoclonal antibodies or polyclonal
human convalescent serum. Neutralization resistance was
associated with reduced affinity of antibody for the virus and
extended broadly to most monoclonal antibodies tested,
including K3-4C8 and B5-B3 (Table 5). Cross-resistance of
escape mutants to monoclonal antibodies recognizing dif-
ferent neutralization immunogenic sites has not been ob-
served with PV1 or HRV14 and has served to functionally
classify these sites (20, 23). Thus the data shown in Table 5
suggest that the epitopes recognized by K3-4C8, K2-4F2,
and B5-B3 are functionally part of a single immunogenic site.
Despite evidence that the involved antigenic domain is
immunodominant in humans (Table 3), neutralization escape
mutants remained readily detectable in polyclonal antibody-
based immunoassays and radioimmunofocus assays. Also,
whereas binding of related monoclonal antibodies to the
mutants appeared substantially reduced in comparison to
parental HM-175 virus, some degree of antibody binding
persisted (Table 4). Emini et al. (4) have suggested that
neutralization of poliovirus by some monoclonal antibodies
requires the bivalent attachment of antibody to the virus and
may be associated with substantial conformational shifts of
the capsid alluded to above. It is tempting to speculate that
neutralization of HAV has a similar basis, and that some
mutations conferring neutralization resistance may prevent
the bivalent attachment of antibody but still allow monoval-
ent binding of antibody under conditions of reduced affinity.
Significantly, virus with mutations resulting in total elimina-
tion of antibody binding to the dominant immunogenic site
may not have been identified under the conditions we
employed, given the apparent dominance of this antigenic
site and the fact that foci of viral replication are recognized
immunologically in the radioimmunofocus assay.
Neutralization resistance associated with decreased bind-
ing of antibody to virus may result from mutations in the
genomic region encoding the antibody binding site (12, 23).
Alternately, neutralization resistance could result from mu-
tations distant from the binding site, causing either local
perturbations in the antigenic site or a major conformational
alteration of the capsid with potential inhibition of a large
range of antibodies directed against many sites on the capsid
(3). Studies with other picornaviruses (HRV14 and PV1),
when placed in the context of the three-dimensional struc-
ture of the virion determined by X-ray crystallography,
suggest that the site of mutation does in fact reside within or
near the monoclonal antibody binding site (20, 23). A single
amino acid substitution has been identified in the hemagglu-
tinin molecule of some influenza virus escape mutants, and
crystallographic studies have confirmed that one such muta-
tion induces only a local alteration in the conformational
structure of the hemagglutinin molecule (12). Given this
evidence, it is likely that RNA sequence analysis of HAV
neutralization escape mutants will identify the neutralization
epitopes of this virus. Such studies will be required to
ultimately confirm the existence of a single immunodominant
antigenic site on the virus capsid.
Significant antigenic variation has not been identified
among HAV strains (14), and epitopes recognized by the
monoclonal antibodies appear to be highly conserved among
diverse HAV strains (S. M. Lemon et al., unpublished data).
This observation stands in sharp contrast to the frequency
with which neutralization escape mutants with altered mono-
clonal antibody binding characteristics arise in vitro. The
frequency with which normal HM-175 strain HAV survives
a single neutralization reaction varies from 3 x 10-3 for
monoclonal antibodies to 1.3 x 10-5 for immune serum
globluin (J. T. Stapleton, unpublished data), consistent with
the transcriptional error rate known to accompany replica-
tion of RNA viruses (9). Presumably, neutralization-
resistant HAV mutants arise during natural infections but do
not replicate to significant levels in vivo. It is intriguing to
consider, therefore, that the immunodominant neutralization
epitopes of HAV may have a vital functional role in the
replication of the virus in vivo. If this is true, then neutral-
ization escape mutants may have lost a function necessary
for in vivo replication and may be partially or completely
attenuated.
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